Treat parvo. Fight parvo. Stop parvo.
Treat parvo. Fight parvo. Stop parvo.
Canine Parvovirus Monoclonal Antibody is the FIRST and ONLY USDA conditionally approved monoclonal antibody treatment that targets canine parvovirus.
Parvo Kills
While canine parvovirus (CPV) vaccinations are highly effective and widely available, CPV is still a real and ever-present threat to all dogs, with unvaccinated and young puppies the most at risk.
Canine Parvovirus Monoclonal Antibody is finally here.
Fight parvo with Canine Parvovirus Monoclonal Antibody
With just one intravenous dose, Canine Parvovirus Monoclonal Antibody (CPMA) may shorten the course of the disease and improve outcomes.
Targets parvovirus directly
Single-dose efficacy
High safety profile
Can decrease burden of supportive care
Can reduce emotional stress
Well tolerated in puppies as young as 6 weeks of age.1
Two components. One powerful product.
CPMA is composed of a dog constant region and a rat variable region. These two elements work together to neutralize canine parvovirus in vivo by selectively binding and blocking the virus from entering and destroying enterocytes.
Targeted Efficacy
After challenged with virulent CPV-2b, zero dogs died when treated with Canine Parvovirus Monoclonal Antibody.1
Parvo kills. Now you can fight back.
Contact your Elanco sales representative about CPMA to fight back against Parvo.
Parvo Resources
Product Detailer
1 Elanco Animal Health. Data on file.